23 RESULTS
Go to another page:
COMMENT The study by DeKosky does not allow for conclusions about whether or not the cholinergic deficit is present at early stages of AD. The data show that there are differences in ChAT activity between a "no cognitive impairment" (NCI) group and a &q
COMMENT This is an important finding that adds to the human evidence pointing to a cholinergic-amyloid connection. Our group has contributed by showing that both muscarinic agonists and acetylcholinesterase inhibitors lower CSF and cortical ABeta levels in normal
COMMENT The NEJM article is good for reminding us that blocking muscarinic receptors may impair cognition and alter perception in anyone, but especially in the elderly. As loss of cortical cholinergic afferents is a normal aging change in humans, the elderly are
COMMENT The epidemiological evidence should now be regarded as strongly against a protective role for smoking in Alzheimer's disease. Although several early prevalence studies showed that AD was less prevalent in elderly smokers, at least one large incidence
COMMENT This data confirms our work, done in collaboration with Abraham Fisher, showing that AF267B and two other of his M1 agonists (AF102B, AF150S) all lower CSF and cortical Aβ concentrations in normal rabbits [1]. This confirms many years of in vitro work goi
COMMENT The Alzheimer's Disease Cooperative Study Group MCI trial results regarding donepezil are very encouraging and should be used to stimulate a primary prevention trial. The New England Journal report did not offer a molecular mechanism to explain donep
COMMENT The paper by LaFerla and colleagues adds to considerable evidence suggesting that M1 receptor activation leads to decreased amyloidogenic processing of APP while reduced M1 receptor activation, by means of either pharmacological agents or cholinergic lesi
COMMENT Interesting paper and nice to see some experimental work being done in this area. I would like to refer readers in this field to our recent papers (below), which confirm earlier work by several investigators that olfactory bulb is universally affected in
COMMENT This is an impressive result, agreed. Just would like to point out that the most likely and earliest entry point for an exogenous process would be through the olfactory bulb, not the gut. Our thorough survey of the peripheral nervous system in subjects wi
COMMENT The study by DeKosky does not allow for conclusions about whether or not the cholinergic deficit is present at early stages of AD. The data show that there are differences in ChAT activity between a "no cognitive impairment" (NCI) group and a &q
COMMENT This interesting study suggests a molecular mechanism that may explain how CAA contributes to dementia. Clinical studies have indicated that CAA contributes to the dementia in AD, and it has been apparent for decades that CAA eventually results in vascula
COMMENT This paper describes a new staging system for all Lewy body disorders and has been badly needed as the two prior major staging systems have failed to classify 40-60 percent of cases. The major differences from prior staging methods are that the rules for
COMMENT I would note that since the overall prevalence of melanoma in Parkinson's disease (PD) is pretty low, it is difficult to see a large role for melanoma-related mechanisms in PD, or vice versa. Also, the extra medical attention that a subject gets afte
COMMENT I think the results raise several questions and have some implications for the disease in humans, but I think it is also exciting that some of the implications and hypotheses arising from the finding can be tested in the transgenic mouse model used. For h
COMMENT These new contributions to the history of Alzheimer disease further illuminate the setting in which Alzheimer made his original observations. I look forward to reading the issue coming out of the Tubingen conference. Many thanks to Andre Delacourte for hi
Go to another page:
